Sponsored Links

CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln

Tue Jul 30, 2013 6:23pm EDT

(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)

July 30 (Reuters) - Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.

Cubist said it would buy all outstanding shares of Optimer for a total of $15.75 per share in cash, including contingency payments. The offer represents a premium of 18 percent on Tuesday's closing price.

Cubist said it would pay a total of $15.50 per share for Trius, including contingency payments. The offer represents a premium of 32 percent to the stock's closing price on Tuesday. (Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel)

 
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.